In summary, we present here the first large-scale ex vivo drug screening in a metastatic parotid squamous cell carcinoma together with use of HER2-targeted therapies adding one more case example to the existing medical literature supporting the use of HER2-directed therapies for a subset of salivary gland tumors. This evidence concerns the gene ERBB2 and tumor of salivary gland.